Want to see OKUR full AI Analyst Report?
OKUR Stock Chart & Stats
$5.00
-$0.05(-0.63%)
At close: 4:00 PM EST
$5.00
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$1.91 - $5.38
Previous CloseN/A
Volume8.61K
Average Volume (3M)86.56K
Market Cap
$166.03M
Enterprise Value-$133.04M
Total Cash (Recent Filing)$192.11M
Total Debt (Recent Filing)$409.00K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 18, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.33
Shares Outstanding40,395,480
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap-0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit655.36
Enterprise Value/Ebitda2.30
Forecast
1Y Price Target
$23.00Price Target Upside360.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.79
Revenue Forecast (FY)$666.67K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and materially improved equity/assets provide financial flexibility for a development-stage biotech. Sustained capitalization reduces immediate solvency risk, enabling multi-stage clinical programs to proceed without near-term debt pressure.
Secured Development FundingA $150M institutional private placement materially extends runway and underwrites planned IND-enabling and clinical activities. This lowers short-term financing risk and supports execution on next-gen PI3Kα candidates rather than relying solely on dilutive spot financings.
Pipeline Progress & Clear MilestonesCompleted dose-escalation enrollment and planned IND submissions establish a defined development roadmap. Clear program milestones through 2027 create tangible technical readouts and regulatory catalysts that, if met, can sustainably advance value creation.
Bears Say
Persistent Cash BurnOngoing, large negative free cash flow and widening net losses are structural for a pre-revenue biotech and drive recurring funding needs. Continued cash burn pressures strategic optionality and elevates dilution or financing risk if development timelines slip.
Dilution / Share OverhangThe sizable private placement and immediately exercisable pre-funded warrants increase share count and create resale overhang. This structural dilution can compress per-share economics and constrain shareholder upside absent commensurate R&D success.
Clinical Execution RiskPivoting away from OKI-219 and relying on IND submissions for new candidates concentrates risk on timely development and regulatory acceptance. Missed IND or clinical setbacks would materially delay any path to revenue and exacerbate funding dependence.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.91 and its highest was $5.38 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $166.03M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 33 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on May 05, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.742 by -$0.368.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -0.58.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 40,395,480 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.742. Following the earnings report the stock price went down -9.956%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (360.00% Upside)
$23.00 (360.00% Upside)
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
-61.02%
Trailing 12-Months
Asset Growth
98.93%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
OKUR Stock 12 Month Forecast
Average Price Target
$23.00
▲(360.00% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
1.69% Mutual Funds
63.84% Other Institutional Investors
28.78% Public Companies and
Individual Investors